Wedbush Reiterates Outperform Rating on Moonlake Immunotherapeutics (MLTX)

September 29, 2025 6:56 AM EDT Send to a Friend
Wedbush analyst Yun Zhong reiterated an Outperform rating and $80.00 price target on Moonlake Immunotherapeutics (NASDAQ: MLTX).The analyst comments "We ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login